… compare bevacizumab–erlotinib versus erlotinib alone in the … Efficacy endpoints (eg, overall
survival and time from enrolment … Osimertinib was administered in the second line, third line, …

… as first-line therapies in targeted therapy research include erlotinib (8) and gefitinib (9); …
, the present study indicated that, compared with the control group, the third-line treatment of …

… , we designed this randomized, phase-2 study comparing the efficacy and tolerability of
erlotinib 100 mg/d vs. gefitinib 250 mg/d in patients with EGFR-mutated advanced NSCLC. …

… ) compared with placebo as a third-line or subsequent therapy in patients with non-small cell
lung cancer (… The most frequently used EGFR TKIs were gefitinib, erlotinib, and icotinib. For …

… as third-line treatment agent in non-oncogene driven … In the univariate analysis, there was
a significant difference in the … ), such as gefitinib, afatinib, and erlotinib, are recommended …

… efficacy and acceptable toxicity of apatinib plus gefitinib as a … trial comparing oral VEGFR2
TKI, apatinib, plus gefitinib versus … therapy for locally advanced and metastatic non-small cell …

… We aimed to evaluate the efficacy of anlotinib in patients with … common targeted agents were
gefitinib, erlotinib, and icotinib. … -Lung 8 trial compared the efficacy of afatinib and erlotinib in …

… with erlotinib plus bevacizumab compared with erlotinib … efficacy has been observed in
patients with primary erlotinib … received third-line, and half received fourth- or later line treatment, …

… Non–small cell lung cancer … The efficacy of erlotinib was revealed by BR.21 study, in which
patients with … The SIGN and INTEREST trials compared gefitinib with docetaxel in patients …

… pemetrexed + gefitinib (P + G) compared with gefitinib monotherapy. … Primary efficacy and
safety results of this study have been … tyrosine kinase inhibitors in non–small cell lung cancer …